Benzinga · Feb 18, 2026
NASDAQ · ATRC
AtriCure, Inc.
Healthcare · Medical - Instruments & Supplies
$53.68
Up+$0.25 (+0.47%)
Updated Oct 7, 2026, 3:17 PM
SID Score
6.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.06B
- P/E ratio
- -68.62
- Dividend yield
- 0.00%
- 52-week range
- $25.36 – $61.70
- Volume
- 863.66K
- Avg. volume
- 515.68K
Price performance · ATRC
ATRC price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
ATRC closed at $53.68 after 21 trading sessions, down 0.09% for the selected period.
- Last close
- $53.68
- Period change
- -0.09%
- Period low
- $52.96
- Period high
- $60.77
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $55.97 | $56.58 | $53.43 | $53.68 | 863.66K |
| Oct 5, 2026 | $54.14 | $56.60 | $53.86 | $56.37 | 1.1M |
| Oct 2, 2026 | $52.51 | $55.25 | $52.00 | $55.14 | 1.62M |
| Oct 1, 2026 | $56.52 | $56.99 | $52.60 | $53.59 | 1.97M |
| Sep 30, 2026 | $58.01 | $58.60 | $56.15 | $56.20 | 1.11M |
| Sep 29, 2026 | $58.58 | $59.05 | $56.585 | $58.05 | 876.28K |
| Sep 28, 2026 | $57.56 | $58.49 | $56.90 | $58.41 | 1.16M |
| Sep 25, 2026 | $60.85 | $61.32 | $57.89 | $58.38 | 1.59M |
| Sep 24, 2026 | $59.63 | $61.70 | $59.13 | $60.77 | 1.31M |
| Sep 23, 2026 | $58.92 | $61.475 | $58.72 | $59.955 | 1.21M |
| Sep 22, 2026 | $58.62 | $59.69 | $57.935 | $58.83 | 872.57K |
| Sep 21, 2026 | $58.23 | $59.105 | $56.97 | $58.32 | 1.04M |
| Sep 18, 2026 | $58.51 | $59.88 | $57.98 | $58.10 | 8.67M |
| Sep 17, 2026 | $57.96 | $59.59 | $57.31 | $59.12 | 1.54M |
| Sep 16, 2026 | $55.66 | $57.25 | $55.66 | $57.14 | 1.22M |
| Sep 15, 2026 | $56.00 | $56.78 | $54.65 | $56.22 | 1.43M |
| Sep 14, 2026 | $54.84 | $56.02 | $54.81 | $55.79 | 1.15M |
| Sep 11, 2026 | $53.53 | $55.16 | $53.52 | $54.54 | 1.1M |
| Sep 10, 2026 | $52.31 | $53.66 | $51.86 | $52.96 | 961.95K |
| Sep 9, 2026 | $53.155 | $53.705 | $51.965 | $53.03 | 1.66M |
| Sep 8, 2026 | $54.31 | $55.72 | $51.735 | $53.73 | 1.88M |
Latest ATRC news
The latest Smart Investors Daily articles mentioning ATRC.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ATRC research
Overview
Company profile and research snapshot.
Company profile
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $59.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 2, 2026 | Freedom Capital Markets | Hold | — |
| Sep 2, 2026 | Needham | Buy | — |
| Aug 27, 2026 | Piper Sandler | Overweight | — |
| Aug 24, 2026 | BTIG | Buy | — |
| Jul 28, 2026 | UBS | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 18, 2026
Canaccord Genuity Maintains Buy on AtriCure, Lowers Price Target to $53
Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $64 to $53.
Benzinga · Feb 18, 2026
UBS Maintains Buy on AtriCure, Lowers Price Target to $55
UBS analyst Danielle Antalffy maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $60 to $55.
Benzinga · Feb 18, 2026
AtriCure shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY26 sales guidance with its midpoint above estimates. Also, the company issued FY26 EPS guidance above estimates.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
